

Keywords: pancreatic cancer; adjuvant chemotherapy; elderly

Adjuvant chemotherapy in elderly patients with pancreatic cancer

A M Nagrial¹, D K Chang^{1,2,3,4}, N Q Nguyen¹, A L Johns¹, L A Chantrill^{1,5}, J L Humphris¹, V T Chin¹, J S Samra⁶, A J Gill^{7,8}, M Pajic¹, Australian Pancreatic Cancer Genome Initiative¹, M Pinese¹, E K Colvin¹, C J Scarlett^{1,9}, A Chou^{1,10}, J G Kench^{1,11}, R L Sutherland^{1,12}, L G Horvath^{1,13} and A V Biankin^{*,1,2,3,4}

¹The Kinghorn Cancer Centre, and the Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia; ²Department of Surgery, Bankstown Hospital, Eldridge Road, Bankstown, Sydney NSW 2200, Australia; ³South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool NSW 2170, Australia; ⁴Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, Scotland, UK; ⁵Macarthur Cancer Therapy Centre, Campbelltown, NSW 2560, Australia; ⁶Department of Surgery, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; ⁷Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; ⁸Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia; ⁹School of Environmental and Life Sciences, University of Newcastle, Ourimbah, NSW 2258, Australia; ¹⁰Department of Anatomical Pathology, St. Vincent's Hospital, Darlinghurst, Sydney, NSW 2010, Australia; ¹¹Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia; ¹²St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia and ¹³Department of Medical Oncology, Sydney Cancer Centre, Sydney, NSW 2050, Australia

Background: Adjuvant chemotherapy improves survival for patients with resected pancreatic cancer. Elderly patients are under-represented in Phase III clinical trials, and as a consequence the efficacy of adjuvant therapy in older patients with pancreatic cancer is not clear. We aimed to assess the use and efficacy of adjuvant chemotherapy in older patients with pancreatic cancer.

Methods: We assessed a community cohort of 439 patients with a diagnosis of pancreatic ductal adenocarcinoma who underwent operative resection in centres associated with the Australian Pancreatic Cancer Genome Initiative.

Results: The median age of the cohort was 67 years. Overall only 47% of all patients received adjuvant therapy. Patients who received adjuvant chemotherapy were predominantly younger, had later stage disease, more lymph node involvement and more evidence of perineural invasion than the group that did not receive adjuvant treatment. Overall, adjuvant chemotherapy was associated with prolonged survival (median 22.1 vs 15.8 months; $P < 0.0001$). Older patients (aged ≥ 70) were less likely to receive adjuvant chemotherapy (51.5% vs 29.8%; $P < 0.0001$). Older patients had a particularly poor outcome when adjuvant therapy was not delivered (median survival = 13.1 months; HR 1.89, 95% CI: 1.27–2.78, $P = 0.002$).

Conclusion: Patients aged ≥ 70 are less likely to receive adjuvant therapy although it is associated with improved outcome. Increased use of adjuvant therapy in older individuals is encouraged as they constitute a large proportion of patients with pancreatic cancer.

Pancreatic cancer is the fourth leading cause of cancer death in Western societies, with a 5-year survival rate of $< 5\%$ (Jemal *et al*, 2008). Operative resection remains the primary treatment modality

and the only chance of cure (Yeo *et al*, 1997). Those who undergo resection still only have a median survival of 14–20 months and a 5-year survival rate of $\sim 10\%$ with surgery alone and up to 25%

*Correspondence: Dr AV Biankin; E-mail: andrew.biankin@glasgow.ac.uk

Received 15 July 2013; revised 9 October 2013; accepted 21 October 2013; published online 21 November 2013

© 2014 Cancer Research UK. All rights reserved 0007–0920/14



with adjuvant chemotherapy (Neoptolemos *et al*, 2001). Patterns of disease recurrence and the rapid demise of a high proportion of patients with pancreatic cancer even after complete surgical resection suggests that occult metastatic disease is often present at the time of surgery (Barugola *et al*, 2007; Schnelldorfer *et al*, 2008). Thus, it is clear that loco-regional therapies alone are usually not curative and systemic therapies need to be considered in the majority of patients following resection.

In pancreatic cancer, chemotherapy appears to be most effective in the adjuvant setting. In 2001, ESPAC-1 compared 5-fluorouracil, a pyrimidine analogue-based agent, to observation following resection and showed that chemotherapy delayed time to recurrence by 5.9 months and also improved overall survival (19.7 vs 14.0 months; $P=0.0005$) (Neoptolemos *et al*, 2001, 2004). In addition, CONKO-001 independently showed that adjuvant Gemcitabine, a nucleoside analogue, improved a 5-year survival of 10% after surgery alone to 20–25% (Oettle *et al*, 2007). Adjuvant Gemcitabine, owing to its favourable toxicity profile, has become the standard of care for this disease (Neoptolemos *et al*, 2010).

Approximately 60% of patients with pancreatic cancer are aged 65 and over (National Cancer Institute, 2010); however, patients enrolled in ESPAC-1 and CONKO-001 had a younger median age of 60 and 61, respectively (Neoptolemos *et al*, 2004; Oettle *et al*, 2007). It is increasingly recognised that elderly patients are under-represented in cancer trials and that well-selected elderly patients can undergo aggressive surgery for pancreatic cancer (Hutchins *et al*, 1999; Lee *et al*, 2010). This is an important issue in an ageing population as cancer is still a major cause of death in this age group (Edwards *et al*, 2002). It remains unclear whether the use of adjuvant chemotherapy in elderly patients with pancreatic cancer is effective, and given that this question is unlikely to be examined in a clinical trial, we assessed the efficacy of adjuvant therapy in a large community cohort.

We show that patients with pancreatic cancer in the community are older than patients included in Phase III clinical trials, and that elderly patients are less likely to receive adjuvant chemotherapy; yet it is well-tolerated and associated with improved outcome. This highlights the need for greater efforts to offer older patients adjuvant therapy and include them in clinical trials.

PATIENTS AND METHODS

Patients and data acquisition. Clinico-pathologic, treatment and outcome data for a cohort of 439 patients with a diagnosis of pancreatic ductal adenocarcinoma who underwent pancreatic resection with curative intent (no macroscopic residual disease) were accrued from 12 hospitals associated with the Australian Pancreatic Cancer Genome Initiative between 1990 to 2011 (APGI; www.pancreaticcancer.net.au) (Table 1). Ethical approval for the study was obtained from the Human Research Ethics Committee at each participating institution.

All cases underwent central pathology review by at least one specialist pancreatic histopathologist (AJG, AC, JGK) who was blinded to the diagnosis and clinical outcomes to verify the diagnosis of pancreatic ductal adenocarcinoma and to define histopathologic features in a standardized manner using a synoptic report developed for the purpose (Gill *et al*, 2009). Tumours were staged according to the AJCC Cancer Staging Manual 7th edition 2009 (Edge and Compton, 2010).

Clinico-pathologic information was acquired initially retrospectively, and became prospective in 2006. Data were extracted from hospital notes (clinical history, preoperative imaging reports such as computed tomography, magnetic resonance imaging, ultrasound and endoscopic ultrasonography, surgeon's operating reports, anaesthesiologists reports and correspondence letters from

surgeon's and medical oncologist's consulting rooms). The date and cause of death were obtained from Cancer Registries and treating clinicians.

Statistical analysis. Overall survival was used as the primary end point and was calculated from the date of diagnosis to the date of death or last clinical follow-up. Univariate Kaplan–Meier analysis of patient, tumour and treatment variables compared median survival using the log-rank test. Variables assessed were sex, age, tumour location, tumour size, lymph node status, stage, differentiation, vascular invasion, perineural invasion, margin status, treatment with adjuvant chemotherapy, palliative chemotherapy and adjuvant radiotherapy. Factors associated with differential survival on univariate analysis with a P -value <0.25 , or with a previously published association were included in Cox proportional hazard multivariate analysis. Variables with a P -value <0.05 were considered statistically significant. Chi-square and Fisher exact tests were used to compare categorical variables and the Student's t -test to compare continuous variables for all analyses. Statistical analysis was performed using Stata version 9.2 (Stata Corp., College Station, TX, USA).

RESULTS

Patient cohort (all patients). The cohort of 439 patients consisted of 230 males and 209 females. The mean age at diagnosis was 65.9, with a median of 67 (range 28 to 87). Ninety-one patients (20.7%) were alive at the censor date of 30 September 2011. Three hundred and eighteen patients (72.5%) died of pancreatic cancer and 29 (6.6%) died of other causes. Twelve patients (2.8%) died within 30 days of surgery and 1 (0.2%) was lost to follow-up. Among those who were still alive, the median follow-up was 22.3 months (range, 0.5–193 months). The median progression-free survival was 12.8 months and the overall survival was 18.1 months.

Detailed clinico-pathologic, treatment and outcome characteristics of the cohort are presented in Table 1: 272 patients (62.0%) had resections with clear margins defined as no tumour present at transected surfaces (Chang *et al*, 2009) and 289 (66.7%) had lymph node metastasis. The majority (86.0%) had tumours of the pancreatic head. Factors associated with improved outcome on univariate analysis included tumours of the pancreatic head (median survival 18.5 vs 12.8 months; $P=0.0008$) compared with body/tail tumours; tumour size >20 mm (25.0 vs 16.6 months; $P=0.0008$); absence of margin involvement (22.1 vs 13.5 months; $P<0.0001$); absence of lymph node metastases (19.7 vs 17.2 months; $P=0.025$); absence of perineural invasion (25.4 vs 17.2 months; $P=0.01$); absence of vascular space invasion (20.5 vs 16.4 months; $P=0.017$) and use of adjuvant chemotherapy (22.1 vs 15.8 months; $P<0.0001$; Table 2). There was no statistically significant difference in survival between young patients (age <70 ; $n=261$) and older patients (defined as patients aged 70 or over; $n=178$) overall (median survival: 20.2 vs 15.8 months; $P=0.085$). Multivariate analysis identified that age, tumour size, margin status, perineural invasion, vascular space invasion and use of adjuvant chemotherapy were independent prognostic factors (Table 3A). The baseline characteristics of our cohort, excluding age, were comparable to Phase III trials in resected pancreatic cancer (Neoptolemos *et al*, 2004; Oettle *et al*, 2007).

A total of 205 patients (46.7%) received adjuvant therapy: 187 patients (42.7%) received adjuvant chemotherapy, whereas 21 (4.8%) received adjuvant radiotherapy and 32 (7.3%) received chemoradiation. The majority of patients who received chemotherapy received Gemcitabine ($n=145$; 79.2%) and the remainder received 5-Fluorouracil and/or platinum-based cytotoxics. The mean number of cycles received was 5. Use of chemotherapy increased significantly after 2001 when clinical trial data began to emerge

Table 1. Baseline characteristics of entire cohort and dichotomized by age groups with univariate analysis

Variables	Entire cohort (N=439)			Young cohort aged <70 years (n=261)			Elderly cohort aged ≥70 years (n=178)			P-value ^a
	n (%)	Median OS (months)	P-value (log-rank)	n (%)	Median OS (months)	P-value (log-rank)	n (%)	Median OS (months)	P-value (log-rank)	
Mean age, years	65.9			59.57			75.2			0.085
Median	67									
Range	28–87									
Gender										0.006
Male	230 (52.4)	18.5	0.795	151 (57.9)	19.6	0.470	79 (44.4)	16.5	0.431	
Female	209 (47.6)	17.8		110 (42.1)	22.1		99 (55.6)	15.6		
Stage										0.008
1A	10 (2.3)	25.7	0.139	7 (2.7)	24.8	0.884	3 (1.7)	40.5	0.037	
1B	21 (4.9)			18 (7.0)			3 (1.7)			
2A	114 (26.4)	17.6		55 (21.4)	19.6		59 (33.7)	15.7		
2B	287 (66.4)			177 (68.9)			110 (62.9)			
Differentiation										0.457
Well	33 (8.9)	26.2	0.373	16 (7.4)	26.2	0.576	17 (10.9)	21.8	0.425	
Moderate	238 (63.8)	17.5		139 (64.1)	20.2		99 (63.5)	13.3		
Poor	102 (27.3)	18.1		62 (28.6)	19.6		40 (25.6)	16.0		
Tumour location										0.299
Head	369 (86.0)	18.5	0.021	223 (87.5)	21.3	0.642	146 (83.9)	16.9	0.005	
Body/tail	60 (14.0)	12.8		32 (12.5)	19.3		28 (16.1)	8.9		
Tumour size (mm)										0.827
≤20	103 (23.6)	25.0	0.001	62 (23.9)	27.5	0.049	41 (23.0)	24.4	0.005	
>20	334 (76.4)	16.6		197 (76.1)	19.4		137 (77.0)	12.8		
Margins (0 mm)										0.345
Clear	272 (62.0)	22.1	<0.0001	157 (60.2)	23.4	<0.0001	115 (64.6)	18.0	<0.0001	
Involved	167 (38.0)	13.5		104 (39.8)	16.0		63 (35.4)	11.0		
Lymph nodes										0.121
Negative	144 (33.3)	19.7	0.025	78 (30.4)	21.5	0.082	66 (37.5)	18.0	0.122	
Positive	289 (66.7)	17.2		179 (69.6)	19.3		110 (62.5)	13.1		
Perineural invasion										0.280
Negative	102 (23.6)	25.4	0.010	56 (21.8)	27.5	0.113	46 (26.3)	20.9	0.022	
Positive	330 (76.4)	17.2		201 (78.2)	19.5		129 (73.7)	13.3		
Vascular invasion										0.012
Negative	224 (52.1)	20.5	0.017	120 (47.1)	20.5	0.845	104 (59.4)	19.3	<0.0001	
Positive	206 (47.9)	16.4		135 (52.9)	21.5		71 (40.6)	12.0		
Radiotherapy										0.040
No adjuvant	416 (95.2)	18.1	0.752	243 (93.5)	19.7	0.830	173 (97.7)	15.9	0.452	
Adjuvant	21 (4.8)	18.6		17 (6.5)	21.5		4 (2.3)	10.7		
Adjuvant chemotherapy										<0.0001
Adjuvant	187 (42.7)	22.1	<0.0001	134 (51.5)	22.5	0.085	53 (29.8)	21.8	0.003	
No adjuvant	251 (57.3)	15.8		126 (48.5)	17.5		125 (70.2)	13.1		
Palliative chemotherapy										0.002
No palliative therapy	314 (71.7)	16.5	0.74	188 (67.9)	18.5	0.266	126 (78.3)	13.3	0.582	
Palliative therapy	124 (28.3)	21.3		89 (32.1)	21.5		35 (21.7)	21.1		
Outcome										
Pancreatic cancer death	318 (72.4)			182 (69.7)			136 (76.4)			0.124
Death – other causes	29 (6.6)			16 (6.1)			13 (7.3)			
Alive	92 (21.0)			63 (24.1)			29 (16.3)			
Median overall survival (months)		18.1			20.2			15.8		0.085

Abbreviation: OS = overall survival.

^aComparison of variables between <70 cohort and ≥70 cohort.

Table 2. Comparison between adjuvant chemotherapy group and no adjuvant chemotherapy group in each cohort

Variables	Entire cohort (N = 439)			Cohort aged <70 years (n = 261)			Cohort aged ≥70 years (n = 178)		
	Adjuvant chemotherapy (n = 187)	No adjuvant chemotherapy (n = 251)	P-value ^a	Adjuvant chemotherapy (n = 134)	No adjuvant chemotherapy (n = 126)	P-value ^a	Adjuvant chemotherapy (n = 53)	No adjuvant chemotherapy (n = 125)	P-value ^a
Mean age, years	63.4	67.8	<0.0001	59.22	59.88	0.504	73.87	75.77	<0.001
Gender									
Male	107 (57.2)	122 (48.6)	0.08	79 (59.0)	71 (56.4)	0.671	28 (52.8)	51 (40.8)	0.140
Female	80 (42.8)	129 (51.4)		55 (41.0)	55 (43.7)		25 (47.2)	74 (59.2)	
Stage									
1A	1 (0.5)	9 (3.7)	0.04	1 (0.8)	6 (4.8)	0.013	0 (0.0)	3 (2.5)	0.013
1B	7 (3.8)	14 (5.7)		4 (3.0)	14 (11.3)		3 (5.7)	0 (0.0)	
2A	41 (22.2)	73 (29.7)		28 (21.1)	27 (21.8)		13 (24.5)	46 (37.7)	
2B	136 (73.5)	150 (61.0)		99 (74.4)	77 (62.1)		37 (69.8)	73 (59.8)	
Differentiation									
Well	10 (7.2)	23 (9.8)	0.72	6 (6.0)	10 (8.6)	0.738	4 (10.3)	13 (11.1)	0.888
Moderate	90 (64.7)	148 (63.2)		64 (64.0)	75 (64.1)		26 (66.7)	73 (62.4)	
Poor	39 (28.1)	63 (26.9)		30 (30.0)	32 (27.4)		9 (23.1)	31 (26.5)	
Tumour location									
Head	159 (88.8)	209 (83.9)	0.16	116 (89.2)	106 (85.5)	0.368	43 (87.8)	103 (82.4)	0.387
Body/tail	20 (11.2)	40 (16.1)		14 (10.8)	18 (14.5)		6 (12.2)	22 (17.6)	
Tumour size (mm)									
≤20	44 (23.7)	59 (23.6)	0.99	34 (25.6)	28 (22.4)	0.552	10 (18.9)	31 (24.8)	0.390
>20	142 (76.3)	191 (76.4)		99 (74.4)	97 (77.6)		43 (81.1)	94 (75.2)	
Margins (0 mm)									
Clear	112 (59.9)	159 (63.3)	0.49	79 (59.0)	77 (61.1)	0.723	33 (62.3)	82 (65.6)	0.670
Involved	75 (40.1)	92 (36.7)		55 (41.0)	49 (38.9)		20 (37.7)	43 (34.4)	
Lymph nodes									
Negative	49 (26.3)	95 (38.6)	0.008	33 (24.8)	45 (36.6)	0.041	16 (30.2)	50 (40.7)	0.188
Positive	137 (73.7)	151 (61.3)		100 (75.2)	78 (63.4)		37 (69.8)	73 (59.4)	
Perineural invasion									
Negative	32 (17.4)	70 (28.3)	0.008	21 (15.9)	35 (28.2)	0.017	11 (21.2)	35 (28.5)	0.316
Positive	152 (83.5)	177 (71.7)		111 (84.1)	89 (71.8)		41 (78.9)	88 (71.5)	
Vascular invasion									
Negative	88 (47.8)	136 (55.5)	0.12	57 (43.2)	63 (51.6)	0.177	31 (59.6)	73 (59.4)	0.974
Positive	96 (52.2)	109 (44.4)		75 (56.8)	59 (48.4)		21 (40.4)	50 (40.7)	
Palliative chemotherapy									
No palliative	137 (73.3)	177 (70.5)	0.528	91 (67.9)	81 (64.3)	0.537	46 (86.8)	96 (76.8)	0.129
Palliative	50 (26.7)	74 (29.5)		43 (32.1)	45 (35.7)		7 (13.2)	29 (23.2)	
Radiotherapy									
No adjuvant	169 (90.9)	247 (98.4)	<0.00001	119 (88.8)	124 (98.4)	0.022	50 (96.2)	123 (98.4)	0.012
Adjuvant	17 (9.1)	4 (1.6)		15 (11.2)	2 (1.6)		2 (3.9)	2 (1.6)	
Outcome									
Pancreatic cancer death	112 (59.8)	206 (82.1)	<0.0001	83 (61.9)	99 (78.6)	0.003	29 (54.7)	107 (85.6)	<0.0001
Death – other causes	8 (4.3)	21 (8.4)		5 (3.7)	11 (8.7)		3 (5.7)	10 (8.0)	
Alive	67 (35.8)	24 (9.6)		46 (34.3)	16 (12.7)		21 (39.6)	8 (6.4)	
Median overall survival (months)	22.1	15.8	<0.0001	22.5	17.5	0.085	21.8	13.1	0.003

^aComparison of variables between adjuvant chemotherapy and no adjuvant chemotherapy within each cohort.

Table 3. Final multivariate model of overall survival for entire cohort, elderly cohort and young patient cohort

Variables	Hazard ratio (95% CI)	P-value
(A) Entire cohort		
Age, ≥70 years	1.35 (1.07–1.70)	0.01
Tumour size, > 20 mm	1.43 (1.10–1.85)	0.007
Margins, involved	1.69 (1.35–2.12)	<0.0001
Perineural invasion, positive	1.33 (1.02–1.72)	0.033
Vascular invasion, positive	1.37 (1.09–1.71)	0.007
Adjuvant chemotherapy, none	1.38 (1.21–1.50)	<0.0001
(B) Older cohort (age ≥70 years)		
Tumour location, head	1.37 (1.03–1.59)	0.037
Margins, involved	1.98 (1.40–2.79)	<0.0001
Vascular invasion, positive	2.79 (1.60–3.24)	<0.0001
Adjuvant chemotherapy, none	1.47 (1.21–1.64)	0.002
(C) Young cohort (age <70 years)		
Margins, involved	1.81 (1.36–2.42)	<0.0001
Adjuvant chemotherapy, none	1.35 (1.02–1.79)	0.035

Abbreviation: CI = confidence interval.

supporting its use. Pre-2001, only 19.1% of patients received adjuvant chemotherapy compared with 56.5% after 2001 ($P < 0.0001$). In addition, the use of Gemcitabine increased post 2001 (8.0% vs 47.8%; $P < 0.0001$) (Figure 1A).

Patients that receive adjuvant chemotherapy have poor prognostic factors. To further clarify the role of adjuvant chemotherapy, patients were stratified into two groups of ‘adjuvant chemotherapy’ and ‘no adjuvant chemotherapy’. Patient, tumour and treatment characteristics of the two groups were compared (Table 2). The group that received adjuvant chemotherapy had more poor prognostic factors including more advanced stage (stage 2B; 73.5% vs 61.0%; $P = 0.04$), more tumours with positive lymph nodes (73.7% vs 61.3%; $P = 0.008$) and a higher prevalence of perineural invasion (83.5% vs 71.7%; $P = 0.008$). In addition, the group that had adjuvant chemotherapy was significantly younger (63.4 vs 67.8 years; $P < 0.0001$). Despite the constellation of adverse features, the group that received adjuvant chemotherapy had a significantly better median survival (Figure 1B).

Older patients that do not receive adjuvant therapy have a poor prognosis. To investigate the relationship between age and outcome, patients were stratified into two groups of ‘cohort younger than 70’ and ‘cohort 70 or older’. Sex, tumour pathological characteristics and treatment (adjuvant chemotherapy, palliative chemotherapy and radiotherapy) were compared between the two




Figure 1. (A) Use of adjuvant chemotherapy before and after publication of ESPAC-1 in 2001. (B) Kaplan–Meier survival curves of the entire cohort stratified by use of adjuvant chemotherapy ($N = 439$). (C) Kaplan–Meier survival curves of sub-groups (<70 and ≥70) stratified by use of adjuvant chemotherapy.

groups. A total of 178 patients (40.5%) were ≥ 70 years old. The younger cohort (< 70) had more poor prognostic factors; more males (57.9% vs 44.4%; $P = 0.006$), more advanced stage (stage 2B; 68.1% vs 62.9%; $P = 0.008$) and more patients with evidence of vascular space invasion (52.1% vs 40.6%; $P = 0.012$). Adjuvant chemotherapy (51.5% vs 29.8%; $P < 0.0001$), palliative chemotherapy (33.8% vs 20.2%; $P = 0.002$) and adjuvant chemoradiation (10.0% vs 3.4%; $P = 0.009$) were all less frequently administered in the older (≥ 70) patient subgroup (Table 1). The 30-day mortality did not differ (1.9% vs 4.0%; $P = 0.187$) and the mean number of cycles of chemotherapy received was the same in the two sub-groups (5.2 vs 5.2; $P = 0.922$). The cause of death in patients aged ≥ 70 was predominantly pancreatic cancer (76.4%) and did not significantly differ from young patients. Only 7.3% of pancreatic cancer patients aged ≥ 70 died of causes other than cancer, again no different to younger patients (7.3% vs 6.1%; $P = 0.124$).

Not receiving adjuvant chemotherapy was an independent poor prognostic factor in the older population (HR 1.89, 95% CI: 1.27–2.78, $P = 0.002$) (Table 3B). Figure 1C shows the cohort divided into four groups based on age (< 70 and ≥ 70) and use of adjuvant chemotherapy (adj and no adj). Patients aged ≥ 70 who did not receive adjuvant chemotherapy had an extremely poor outcome with a median survival of only 13.1 months despite favourable clinico-pathologic features, whereas elderly patients who received adjuvant chemotherapy had an outcome similar to young patients (21.8 vs 22.5; $P = 0.576$) (Table 2; Figure 1C). In addition, patients aged ≥ 70 who did not receive adjuvant chemotherapy were less likely to receive palliative chemotherapy than the corresponding group of patients aged < 70 (23.2% vs 35.7%; $P = 0.03$); however, palliative chemotherapy had no effect on survival in either group on univariate or multivariate analysis.

DISCUSSION

Adjuvant chemotherapy improves outcomes for patients with pancreatic cancer in the community and supports clinical trial data even though clinical trials selectively recruit patients (Neoptolemos *et al*, 2004; Oettle *et al*, 2007). Patients in the community are older than patients in clinical trials, and older patients are less likely to receive adjuvant therapy, although data from this study suggest that it is associated with improved survival to a similar, if not greater degree as it is for younger patients.

Recently, several studies have examined the role of palliative chemotherapy in advanced pancreatic cancer showing that Gemcitabine in elderly patients is as well-tolerated and equally as effective as in younger patients (Marechal *et al*, 2008; Hentic *et al*, 2011). With regard to adjuvant therapy, a recent population study suggested that adjuvant chemotherapy was less frequently administered to older patients with pancreatic cancer (Davila *et al*, 2009). Previous studies focusing on colon and breast cancer as well as a single institution study in pancreatic cancer suggest that older patients are less likely to receive adjuvant treatment in many different cancer types, although it is associated with improved outcomes (Potosky *et al*, 2002; Bouchardy *et al*, 2003; Barbas *et al*, 2012).

In older patients with cancer, reluctance to administer adjuvant treatment may be based on the perception that they have an increased risk of a non-cancer-related cause of death and therefore the overall benefit of adjuvant therapy is limited. Our study highlights that this is not the case and the predominant cause of death in older patients is still cancer, and not different to a younger population. The mean number of cycles of chemotherapy received by elderly patients was the same as young patients suggesting that once adjuvant treatment was commenced, older patients were equally likely to complete treatment. Importantly, adjuvant

chemotherapy is the only actionable variable associated with improved survival in older patients. Unless further studies emerge suggesting that adjuvant chemotherapy provides unacceptable toxicity in the elderly, efforts to increase the use of adjuvant chemotherapy in older patients may improve overall outcomes, particularly in the setting of ageing populations.

We acknowledge that there are limitations to this study and that a prospective study in older patients would better clarify the role of adjuvant chemotherapy. Such a study may be difficult to conduct given the proven role of adjuvant chemotherapy and unlikely to be undertaken. As the study did not collect preferences data, it is not possible to comment on the reasons that patients did not receive adjuvant treatments. In addition, we cannot be certain that older patients were not more likely to be of a lower performance status following surgery. However, the study found that the post-operative stay following surgery was similar (12 days) as was the post-operative mortality rate. In addition, the rates of adjuvant chemotherapy use have increased since 2001 suggesting that an increase in uptake is possible and may be independent of patient characteristics.

In conclusion, pancreatic cancer is predominantly a cancer of older age groups and therefore is not entirely reflective of patients who were included in published Phase 3 clinical trials. In this study, adjuvant chemotherapy was independently associated with improved outcome in all patients. The benefit of 8.7 months with adjuvant chemotherapy in older patients is clinically significant; however, the utilisation rate of adjuvant treatments is markedly lower than in young patients despite similar clinico-pathologic features. Moreover, older patients who did receive adjuvant chemotherapy were equally likely to complete treatment. Advancing age alone should not preclude the use of adjuvant chemotherapy in this highly lethal disease.

ACKNOWLEDGEMENTS

We thank all the members and administrative staff of the NSW Pancreatic Cancer Network and the Australian Pancreatic Cancer Genome Initiative. For full list of members, please see www.pancreaticcancer.net.au. The funding bodies had no role in the design or conduct of the study. This research was supported by The National Health & Medical Research Council of Australia, The Cancer Council NSW, Cancer Institute NSW, Sydney Catalyst, Royal Australasian College of Surgeons, Royal Australasian College of Physicians, St Vincent's Clinic Foundation, RT Hall Trust, Jane Hemstritch for Phillip Hemstritch and the Avner Nahmani Pancreatic Cancer Foundation.

REFERENCES

- Barbas AS, Turley RS, Ceppa EP, reddy SK, blazer 3RD DG, Clary BM, Pappas TN, Tyler DS, White RR, Lagoo SA (2012) Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. *J Am Geriatr Soc* **60**: 344–350.
- Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A, Salvia R, Bassi C, Pederzoli P (2007) The determinant factors of recurrence following resection for ductal pancreatic cancer. *JOP* **8**: 132–140.
- Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. *J Clin Oncol* **21**: 3580–3587.
- Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV (2009) Margin clearance and outcome in resected pancreatic cancer. *J Clin Oncol* **27**: 2855–2862.
- Davila JA, Chiao EY, Hasche JC, Petersen NJ, Mcglynn KA, Shaib YH (2009) Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. *Pancreas* **38**: e18–e25.

- Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* **17**: 1471–1474.
- Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. *Cancer* **94**: 2766–2792.
- Gill AJ, Johns AL, Eckstein R, Samra JS, Kaufman A, Chang DK, Merrett ND, Cosman PH, Smith RC, Biankin AV, Kench JG (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. *Pathology* **41**: 161–167.
- Hentic O, Dreyer C, Rebours V, Zappa M, Levy P, Raymond E, Ruszniewski P, Hammel P (2011) Gemcitabine in elderly patients with advanced pancreatic cancer. *World J Gastroenterol* **17**: 3497–3502.
- Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. *N Engl J Med* **341**: 2061–2067.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. *CA Cancer J Clin* **58**: 71–96.
- Lee MK, Dinorcja J, Reavey PL, Holden MM, Genkinger JM, Lee JA, Schrope BA, Chabot JA, Allendorf JD (2010) Pancreaticoduodenectomy can be performed safely in patients aged 80 years and older. *J Gastrointest Surg* **14**: 1838–1846.
- Marechal R, Demols A, Gay F, De Maertelaer V, Arvanitaki M, Hendlisz A, Van Laethem JL (2008) Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. *Pancreas* **36**: e16–e21.
- National Cancer Institute, D (2010) Surveillance Research Program, Cancer Statistics Branch Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2007). Released April 2010, based on the November 2009 submission edn.
- Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* **358**: 1576–1585.
- Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, Mckay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA* **304**: 1073–1081.
- Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* **350**: 1200–1210.
- Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* **297**: 267–277.
- Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF (2002) Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. *J Clin Oncol* **20**: 1192–1202.
- Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? *Ann Surg* **247**: 456–462.
- Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. *Ann Surg* **226**: 248–257. discussion 257–260.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>